Zhejiang Anglikang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Anglikang") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions. Recently, Fujian Haixi United Pharmaceutical Co., Ltd. (hereinafter referred to as "Haixi Pharmaceutical"), a subsidiary of the Company, received the isoflurane "Drug Registration Certificate" issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). The relevant information is announced as follows:
002940SZSE
🚨 Material Event
Announcement on Subsidiary Obtaining Drug Registration Certificate
✨ AI Summary
Zhejiang Anglikang Pharmaceutical Co., Ltd. announced that its subsidiary, Fujian Haixi United Pharmaceutical Co., Ltd., has received a drug registration certificate for isoflurane from the National Medical Products Administration. This approval enhances the company's generic drug pipeline and competitiveness. However, the pharmaceutical sales may be affected by national policies and market changes, leading to uncertainties.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.